Clinical Trials Analysis

Lilly buys 4E in non-opioid pain push: what investors should watch

FDA · moderate to severe acute pain · 6 min

Merck and Gilead report mixed outcomes in lung cancer and HIV studies

HIV · 6 min

Novartis remibrutinib wins Phase 3 in CSU: what it means

chronic spontaneous urticaria · 9 min

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

chronic spontaneous urticaria · 8 min

Lenacapavir posts 100% HIV prevention in PURPOSE 1

FDA · HIV · 8 min

Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial

FDA · Alzheimer's disease · 6 min

Eli Lilly raises 2026 revenue guidance on Mounjaro demand

EMA · obesity · 6 min

Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications

obesity · 5 min

Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data

migraine · 4 min

Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond

pancreatic cancer · 4 min

Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets

breast cancer · 4 min

FDA Flavored Vape Ban: Youth Risk and Pharma Implications

FDA · 4 min